41 related articles for article (PubMed ID: 8208555)
1. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder.
Keen AJ; Knowles MA
Oncogene; 1994 Jul; 9(7):2083-8. PubMed ID: 8208555
[TBL] [Abstract][Full Text] [Related]
2. Refinement of the critical genomic region for congenital hyperinsulinism in the Chromosome 9p deletion syndrome.
Banerjee I; Senniappan S; Laver TW; Caswell R; Zenker M; Mohnike K; Cheetham T; Wakeling MN; Ismail D; Lennerz B; Splitt M; Berberoğlu M; Empting S; Wabitsch M; Pötzsch S; Shah P; Siklar Z; Verge CF; Weedon MN; Ellard S; Hussain K; Flanagan SE
Wellcome Open Res; 2019; 4():149. PubMed ID: 32832699
[No Abstract] [Full Text] [Related]
3. Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.
Majumdar S; Gong EM; Di Vizio D; Dreyfuss J; Degraff DJ; Hager MH; Park PJ; Bellmunt J; Matusik RJ; Rosenberg JE; Adam RM
Neoplasia; 2013 Jul; 15(7):749-60. PubMed ID: 23814487
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.
McConkey DJ; Lee S; Choi W; Tran M; Majewski T; Lee S; Siefker-Radtke A; Dinney C; Czerniak B
Urol Oncol; 2010; 28(4):429-40. PubMed ID: 20610280
[TBL] [Abstract][Full Text] [Related]
5. Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).
Pollard C; Smith SC; Theodorescu D
Expert Rev Mol Med; 2010 Mar; 12():e10. PubMed ID: 20334706
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of bladder cancer.
Knowles MA
Int J Clin Oncol; 2008 Aug; 13(4):287-97. PubMed ID: 18704628
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of noninvasive primary urothelial tumours using microarrays.
Aaboe M; Marcussen N; Jensen KM; Thykjaer T; Dyrskjøt L; Orntoft TF
Br J Cancer; 2005 Nov; 93(10):1182-90. PubMed ID: 16265353
[TBL] [Abstract][Full Text] [Related]
8. Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder.
Chaffer CL; Dopheide B; McCulloch DR; Lee AB; Moseley JM; Thompson EW; Williams ED
Clin Exp Metastasis; 2005; 22(2):115-25. PubMed ID: 16086232
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways in bladder cancer.
Williams SG; Stein JP
Urol Res; 2004 Dec; 32(6):373-85. PubMed ID: 15551095
[TBL] [Abstract][Full Text] [Related]
10. Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.
Aveyard JS; Knowles MA
J Mol Diagn; 2004 Nov; 6(4):356-65. PubMed ID: 15507675
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of the mismatch repair system in bladder cancer.
Thykjaer T; Christensen M; Clark AB; Hansen LR; Kunkel TA; Ørntoft TF
Br J Cancer; 2001 Aug; 85(4):568-75. PubMed ID: 11506498
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity in the Hodgkin-Reed Sternberg cell line L1236.
Staratschek-Jox A; Thomas RK; Zander T; Massoudi N; Kornacker M; Bullerdiek J; Fonatsch C; Diehl V; Wolf J
Br J Cancer; 2001 Feb; 84(3):381-7. PubMed ID: 11161403
[TBL] [Abstract][Full Text] [Related]
13. Two target regions of allelic loss on chromosome 9 in urinary-bladder cancer.
Ohgaki K; Minobe K; Kurose K; Iida A; Habuchi T; Ogawa O; Kubota Y; Akimoto M; Emi M
Jpn J Cancer Res; 1999 Sep; 90(9):957-64. PubMed ID: 10551324
[TBL] [Abstract][Full Text] [Related]
14. Evidence for two candidate tumour suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumour cell lines.
van Tilborg AA; Groenfeld LE; van der Kwast TH; Zwarthoff EC
Br J Cancer; 1999 May; 80(3-4):489-94. PubMed ID: 10408858
[TBL] [Abstract][Full Text] [Related]
15. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?
Bartlett JM; Watters AD; Ballantyne SA; Going JJ; Grigor KM; Cooke TG
Br J Cancer; 1998 Jun; 77(12):2193-8. PubMed ID: 9649132
[TBL] [Abstract][Full Text] [Related]
16. Quantitative trait loci associated with promoting effects of sodium L-ascorbate on two-stage bladder carcinogenesis in rats.
Kamoto T; Mori S; Murai T; Yamada Y; Makino S; Yoshida O; Hiai H
Jpn J Cancer Res; 1997 Jul; 88(7):633-8. PubMed ID: 9310135
[TBL] [Abstract][Full Text] [Related]
17. Genetics of bladder cancer.
Saran KK; Gould D; Godec CJ; Verma RS
J Mol Med (Berl); 1996 Aug; 74(8):441-5. PubMed ID: 8872857
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumors and its prognostic implications.
Maruno M; Yoshimine T; Muhammad AK; Tokiyoshi K; Hayakawa T
J Neurooncol; 1996 Oct; 30(1):19-24. PubMed ID: 8864999
[TBL] [Abstract][Full Text] [Related]
19. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.
Devlin J; Elder PA; Gabra H; Steel CM; Knowles MA
Br J Cancer; 1996 Feb; 73(4):420-3. PubMed ID: 8595153
[TBL] [Abstract][Full Text] [Related]
20. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
Southgate J; Proffitt J; Roberts P; Smith B; Selby P
Br J Cancer; 1995 Nov; 72(5):1214-8. PubMed ID: 7577470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
